Earnings Review
Glenmark Pharma PAT jumps manifold Q4 despite one-time cost
This story was originally published at 21:18 IST on 29 May 2026
Register to read our real-time news.Informist, Friday, May 29, 2026
Please click here to read all liners published on this story
--Glenmark Pharma Jan-Mar consol PAT INR 3.01 bln vs INR 46.50 mln yr ago
--Glenmark Pharma Jan-Mar consol revenue INR 37.71 bln vs INR 32.56 bln yr ago
--Glenmark Pharma Jan-Mar net profit includes one-time cost INR 3.73 bln
--Glenmark Pharma Jan-Mar profit excluding exceptional cost INR 6.75 bln
--Glenmark Pharma to pay INR 2.5 per share dividend
--Glenmark Pharma FY26 consol net profit INR 13.62 bln vs INR 10.47 bln yr ago
--Glenmark Pharma FY26 consol revenue INR 169.83 bln vs INR 133.22 bln year ago
By Gunjan Rajput
NEW DELHI – Glenmark Pharmaceuticals Ltd.'s net profit during the March quarter surged 65 times on year, driven by strong revenue growth and a low base of last year. However, the earnings were affected by an exceptional charge.
The drugmaker's consolidated net profit surged to INR 3.01 billion in the March quarter from INR 46.5 million a year ago. However, the net profit fell short of analysts' expectations of INR 4.16 billion-INR 5.98 billion.
The company reported a sharp jump in net profit due to a low base of last year, when the company had reported a one-time cost of INR 3.7 billion. The company also reported a one-time cost of INR 3.7 billion in the latest quarter but the impact of somewhat offset by higher revenues. Excluding this cost, net profit was INR 6.75 billion, exceeding the Street's estimates.
The company's consolidated revenue from operations increased 15.8% on year to INR 37.71 billion from INR 32.56 billion a year ago. This was inline with expectations of INR 37 billion-INR 38 billion revenue. More
To read more please subscribe
Share this Story:
